Contact
searchSearch
HMP Global
Podcasts

The Costs, Unmet Needs, and Standard of Care Linked With Multiple Myeloma

Maria Asimopoulos
Julie Gould
10/20/2021

 

Ajai Chari, MD, professor of medicine, hematology, and medical oncology, Mount Sinai,Ajai Chari, MD, professor of medicine, hematology, and medical oncology, Mount Sinai, discusses the unmet need in multiple myeloma (MM), challenges specific to treating this disease, why MM is becoming one of the most costly cancers to treat, and provides an overview of currently available treatment options, including the current standard of care.

Behind the Bill

Behind the Bill
The Medicare Paradox: How Tariffs Could Undermine IRA Drug Pricing Reforms
04/23/2025
Katie Hayes, MJ
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years. While the White...
The Trump administration's...
04/23/2025
First Report Managed Care
Behind the Bill
The Bitter Pill, Now in Motion: Pharma Tariffs Move from Rhetoric to Reality
04/16/2025
Katie Hayes, MJ
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing...
04/16/2025
First Report Managed Care
Behind the Bill
The Bitter Pill: How Tariffs Could Make Generics Less Affordable
04/09/2025
Katie Hayes, MJ
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s...
04/09/2025
First Report Managed Care
Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Treatment Discontinuation Patterns Highlight Need for Tolerable CLL Therapies
05/23/2023
Jolynn Tumolo
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved patients with chronic lymphocytic leukemia who received a variety of therapies in first- and second-line settings.
The real-world study involved...
05/23/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
Type 2 Inflammation Linked With Persistent Allergic Disease
07/14/2023
Jolynn Tumolo
“Identifying individuals at risk for continued rhinitis and asthma allows clinicians to better plan follow-up appointments and improve the selection of patients who might benefit from allergen immunotherapy or treatments targeting type 2...
“Identifying individuals at risk for continued rhinitis and asthma allows clinicians to better plan follow-up appointments and improve the selection of patients who might benefit from allergen immunotherapy or treatments targeting type 2...
“Identifying individuals at risk...
07/14/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Jolynn Tumolo
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Secukinumab Well-Tolerated in Pediatric Patients With Plaque Psoriasis
08/29/2023
Jolynn Tumolo
“Secukinumab was equally well tolerated in pediatric patients across age and bodyweight subgroups, and the overall safety profile was consistent with that of adult patients, with no new or unexpected safety signals,” said researchers.
“Secukinumab was equally well tolerated in pediatric patients across age and bodyweight subgroups, and the overall safety profile was consistent with that of adult patients, with no new or unexpected safety signals,” said researchers.
“Secukinumab was equally well...
08/29/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use